Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Michael O. Childress"'
Autor:
Nelly O. Elshafie, Michael Gribskov, Nathanael I. Lichti, Ekramy E. Sayedahmed, Michael O. Childress, Andrea Pires dos Santos
Publikováno v:
FEBS Open Bio, Vol 14, Iss 11, Pp 1899-1913 (2024)
Diffuse large B‐cell lymphoma (DLBCL) is the most prevalent subtype of non‐Hodgkin lymphoma (NHL) in domestic dogs, with many similarities to its human counterpart. The progression of the disease is rapid, and treatment must be initiated early to
Externí odkaz:
https://doaj.org/article/9a51b6ad30a04c1087d67b5b84f7f347
Autor:
Nelly O. Elshafie, Michael Gribskov, Nathanael I. Lichti, Ekramy. E. Sayedahmed, Michael O. Childress, Andrea P. dos Santos
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionLymphoma is a common canine cancer with translational relevance to human disease. Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype, contributing to almost fifty percent of clinically recognized lymphoma cases. Identifyin
Externí odkaz:
https://doaj.org/article/04fc2831d5954499ab23d537c439878e
Autor:
Deepika Dhawan, José A. Ramos-Vara, Sagar M. Utturkar, Audrey Ruple, Sarah A. Tersey, Jennifer B. Nelson, Bruce R. Cooper, Hock Gan Heng, Elaine A. Ostrander, Heidi G. Parker, Noah M. Hahn, Larry G. Adams, Christopher M. Fulkerson, Michael O. Childress, Patty L. Bonney, Christine Royce, Lindsey M. Fourez, Alexander W. Enstrom, Lisbeth A. Ambrosius, Deborah W. Knapp
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundEarly detection and intervention research is expected to improve the outcomes for patients with high grade muscle invasive urothelial carcinoma (InvUC). With limited patients in suitable high-risk study cohorts, relevant animal model resear
Externí odkaz:
https://doaj.org/article/2e6bbabab2074828b5ba17889779a572
Autor:
Blake A. Marcum, Zhe Li, John J. Turek, George E. Moore, David D. Nolte, Michael O. Childress
Publikováno v:
Veterinary Medicine and Science, Vol 7, Iss 3, Pp 665-673 (2021)
Abstract Background Neutropenia is the most common dose‐limiting side effect of cytotoxic chemotherapy in cancer‐bearing dogs. Biodynamic imaging (BDI) is a functional imaging technology that measures dynamic light scattering from living, three
Externí odkaz:
https://doaj.org/article/77dacd601e824251901ec038b34af580
Autor:
Michael O. Childress
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 34, Iss 1, Pp 9-10 (2020)
Externí odkaz:
https://doaj.org/article/16fd7754a6ec4ea8860365b1b619f801
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 3 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf79f886bb73370f4df3bf2b203861b
https://doi.org/10.1158/1078-0432.22478240
https://doi.org/10.1158/1078-0432.22478240
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Fig. 1 depicts the chronology of clinical trial visits and associated procedures for dogs enrolled in this clinical trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e206106b269e032e0544bf85a04ba6
https://doi.org/10.1158/1078-0432.22478255
https://doi.org/10.1158/1078-0432.22478255
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 2 contains the summary comparison of both the Intent-to-treat and Per-protocol analyses of clinical outcomes for dogs enrolled in Standard of Care (SOC) and Standard of Care + sirolimus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22720df435a1efb42466d847b634528d
https://doi.org/10.1158/1078-0432.22478243.v1
https://doi.org/10.1158/1078-0432.22478243.v1
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Purpose:The mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d6627db92e6f7818bf68c257932e98
https://doi.org/10.1158/1078-0432.c.6529898
https://doi.org/10.1158/1078-0432.c.6529898
Autor:
Timothy M. Fan, Chand Khanna, Laura E. Selmic, Daniel L. Gustafson, Sara D. Allstadt, Janean L. Fidel, Michael O. Childress, Kristine Burgess, Antonella Borgatti, Olya Martin, Steven E. Suter, Angela L. McCleary-Wheeler, Cheryl E. Balkman, Lisa G. Barber, Cheryl A. London, Jennifer A. Mahoney, Erika Krick, Raelene M. Wouda, Mary Lynn Higginbotham, Shawna Klahn, Nikolaos Dervisis, Annette N. Smith, Stephanie Lindley, Brandan G. Wustefeld-Janssens, Heather Wilson-Robles, Haley Leeper, Kaitlin M. Curran, Corey Saba, Nicole C. Northrup, J. Paul Woods, Anthony J. Mutsaers, Jennifer L. Willcox, Jenna H. Burton, David M. Vail, Jeffrey N. Bryan, Brian K. Flesner, Kristen Weishaar, Susan E. Lana, Megan E. Brown, William C. Kisseberth, Erika P. Berger, Aswini Cherukuri, Christina N. Mazcko, Amy K. LeBlanc
Supplementary Table 4 contains a summary of the outcomes, with statistical comparisons, of the dogs enrolled in the SOC + sirolimus clinical trial arm. This includes the DFI and outcomes of the groups of dogs stratified by tumor location and ALP stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b4b2bcfb3ae31f8ee4ca6faffb8b03
https://doi.org/10.1158/1078-0432.22478234.v1
https://doi.org/10.1158/1078-0432.22478234.v1